Gemfibrozil

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Gemfibrozil
Gemfibrozil.svg
Systematic (IUPAC) name
5-(2,5-dimethylphenoxy)-2,2-dimethyl-pentanoic acid
Clinical data
Trade names Lopid
AHFS/Drugs.com monograph
MedlinePlus a686002
Pregnancy
category
  • Category C
Legal status
  • By Prescription
Routes of
administration
Oral
Pharmacokinetic data
Bioavailability Close to 100%
Protein binding 95%
Metabolism Hepatic (CYP3A4)
Biological half-life 1.5 hours
Excretion Renal 94%
Feces 6%
Identifiers
CAS Number 25812-30-0 YesY
ATC code C10AB04
PubChem CID 3463
IUPHAR/BPS 3439
DrugBank DB01241 YesY
ChemSpider 3345 YesY
UNII Q8X02027X3 YesY
KEGG D00334 YesY
ChEBI CHEBI:5296 YesY
ChEMBL CHEMBL457 YesY
Chemical data
Formula C15H22O3
Molar mass 250.333 g/mol
Physical data
Melting point 61 to 63 °C (142 to 145 °F)
  (verify)

Gemfibrozil is the generic name for an oral drug used to lower lipid levels. It belongs to a group of drugs known as fibrates. It is most commonly sold as the brand name, Lopid. Other brand names include Jezil and Gen-Fibro.[citation needed]

Development history[edit]

Gemfibrozil was selected from a series of related compounds synthesized in the laboratories of the American company Parke Davis in the late 1970s. It came from research for compounds that lower plasma lipid levels in humans and in animals.[1]

Actions[edit]


Therapeutic effects[edit]

Nontherapeutic effects and toxicities[edit]

Indications[edit]

Contraindications and precautions[edit]

  • Gemfibrozil should not be given to these patients:[citation needed]
    • Hepatic dysfunction
  • Gemfibrozil should be used with caution in these higher risk categories:[citation needed]
    • Biliary tract disease
    • Renal dysfunction
    • Pregnant women
    • Obese patients

Drug interactions[edit]

Environmental data[edit]

Gemfibrozil has been detected in biosolids (the solids remaining after wastewater treatment) at concentrations up to 2650 ng/g wet weight.[3] This indicates that it survives the wastewater treatment process.

References[edit]

  1. ^ Rodney, G; et al. (1976). "The Hypolipidemic Effect of Gemfibrozil (CI-719) in Laboratory Animals". Proc. roy. Soc. Med. 69 (Supplement 2): 6–9. PMC 1864017. PMID 828263. Retrieved 18 April 2015. 
  2. ^ "Gemfibrozil." WebMD.com Accessed 14 June 2014. http://www.webmd.com/drugs/drug-11423-gemfibrozil+oral.aspx
  3. ^ http://water.epa.gov/scitech/wastetech/biosolids/tnsss-overview.cfm

External links[edit]